Pulmonary disease continues to be the third leading cause of death in the United States and is responsible for more than $150 billion in healthcare costs. Due to increasing incidence of COPD and asthma in the United States and worldwide these costs are expected to soar in the coming decades.
Biomodels offers an array of in vivo models to characterize human lung disease. These include hydrochloric acid-induced and LPS-induced models of acute lung injury and COPD. Ovalbumin, house dust mite and cockroach allergen models of allergic asthma, as well as radiation or bleomycin induced lung fibrosis. Each of these models are specifically designed to provide traditional inflammatory measures in conjunction with detailed lung mechanics measures to provide you with outcomes that best predict how your therapeutic will behave in the clinic.